Key Highlights
- The Hologic acquisition by Blackstone and TPG closed on April 7, 2026, with shareholders receiving up to $79 per share.
- The deal structure includes $76 cash upfront plus conditional value rights worth as much as $3 per share based on Breast Health division performance.
- Abu Dhabi Investment Authority and GIC participated as minority investors in the transaction.
- CEO Stephen MacMillan stepped down after over a decade leading the company; Joe Almeida now serves as CEO.
- The company’s common shares stopped trading and Nasdaq delisting became effective.
The women’s health diagnostics company Hologic closed its transition to private ownership on April 7, 2026, as Blackstone and TPG finalized their acquisition worth as much as $79 for each share.
Originally unveiled on October 21, 2025, the buyout secured shareholder backing on February 5, 2026. The deal structure also included participation from an Abu Dhabi Investment Authority subsidiary and a GIC affiliate as minority stakeholders.
Under the agreement terms, stockholders collected $76 in cash per share immediately. Additionally, they received a contingent value right that cannot be traded, potentially delivering another $3 per share across two separate payments of up to $1.50 eachâcontingent on Hologic achieving specific worldwide revenue benchmarks in its Breast Health segment during fiscal 2026 and 2027.
This CVR arrangement means shareholders only realize the complete $79 valuation if the company reaches those performance thresholds. It represents a significant consideration for those monitoring the transaction’s ultimate economic outcome.
Prior to the deal’s completion, Hologic generated $4.13 billion in trailing twelve-month revenue, maintained a 60% gross margin, and held a current ratio exceeding 4. The company commanded a market capitalization of $16.97 billion.
The most recent quarterly performance fell below Wall Street projections. Revenue totaled $1.05 billion versus analyst expectations of $1.07 billion, while adjusted earnings per share reached $1.04 compared to the $1.09 consensus estimate.
Executive Transition
Stephen MacMillan concluded his tenure as CEO upon deal closure, wrapping up more than twelve years leading the organization. Joe Almeida assumed the Chief Executive Officer position effective immediately and now serves as the company’s only board director.
Almeida brings extensive medical technology sector experience. He previously held the Chairman, President and CEO positions at Baxter International from 2016 through early 2025, and occupied identical roles at Covidien before Medtronic’s 2015 acquisition of that company.
The executive appointment reflects the strategic intentions of the new ownersâBlackstone, overseeing $1.3 trillion in assets under management, and TPG, managing $303 billionâto pursue expansion under private equity ownership.
Hologic’s equity arrangements underwent comprehensive restructuring as part of the transaction. Stock option holders and equity award recipients received combinations of cash and CVR-linked payments, while out-of-the-money options were eliminated without compensation.
Public Market Exit
HOLX shares have permanently stopped trading. The organization will complete its delisting from Nasdaq, transitioning to full ownership by the Blackstone-TPG partnership.
Shares concluded their final trading session at $76.01âvirtually matching the 52-week peak of $76.07, demonstrating how accurately the market anticipated the transaction’s finalization.
Six Wall Street analysts had lowered their earnings projections for future periods before the deal closed. The final analyst recommendation on HOLX was a Buy rating with an $83 target price.
InvestingPro had awarded Hologic a “GREAT” financial health rating before the acquisition’s completion.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
